NCT06721962View on ClinicalTrials.gov

Treatment of Moderate to Severe Refractory Crohn's Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 5, 2025

Primary Completion Date

December 15, 2025

Study Completion Date

December 15, 2026

Conditions
Crohns Disease
Interventions
BIOLOGICAL

TRX103

TRX103 is an investigational research product that may treat and provide long term relief to individuals suffering from Crohn's Disease.

DRUG

Cyclophosphamide

Low dose cyclophosphamide conditioning.

Trial Locations (9)

10029

RECRUITING

Mount Sinai Health Systems, New York

44195

RECRUITING

Cleveland Clinic, Cleveland

48109

RECRUITING

University of Michigan, Ann Arbor, Ann Arbor

52242

RECRUITING

University of Iowa, Iowa City

60611

RECRUITING

Northwestern, Chicago

60637

RECRUITING

University of Chicago, Chicago

63110

RECRUITING

Washington University in St. Louis, St Louis

94158

RECRUITING

University of California, San Francisco, San Francisco

95817

RECRUITING

University of California, Davis, Sacramento

All Listed Sponsors
lead

Tr1X, Inc.

INDUSTRY